clofibrate has been researched along with Carbohydrate Inducible Hyperlipemia in 52 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Excerpt | Relevance | Reference |
---|---|---|
"The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
"The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
"Ten patients with type III and 10 with type IV hyperlipoproteinemia participated in a comparative open cross-over study of the effect of acipimox (750 mg/day) and clofibrate (2 g/day) on lipoproteins, apoliproproteins and postheparin lipase activities during 6 weeks." | 2.66 | A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. ( Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A, 1985) |
"Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
"Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
"Treatment with clofibric acid over a long period of time may well give rise to additional reactions through influences exerted upon the insulin level." | 1.26 | [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life]. ( Reuter, W, 1982) |
" All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months." | 1.26 | [Clinical effects and tolerance of etofylline clofibrate]. ( Metz, G; Specker, M; Ziegler, WJ, 1980) |
"Fenofibrate was also found to normalize platelet aggregation in patients with type IIb HLP." | 1.26 | [Pharmacology of fenofibrate (author's transl)]. ( Kritchevsky, D, 1980) |
"Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
"Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration." | 1.26 | Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 50 (96.15) | 18.7374 |
1990's | 2 (3.85) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kaffarnik, H | 2 |
Schneider, J | 2 |
Schubotz, R | 2 |
Zöfel, P | 1 |
Hausmann, L | 2 |
Goebel, KM | 1 |
Sirtori, M | 1 |
Montanari, G | 1 |
Gianfranceschi, G | 1 |
Malacrida, MG | 1 |
Battistin, P | 1 |
Morazzoni, G | 1 |
Tremoli, E | 1 |
Colli, S | 1 |
Maderna, P | 1 |
Sirtori, CR | 1 |
Gawrońska-Szklarz, B | 1 |
Kalinowski, W | 1 |
Wójcicki, J | 1 |
Kesäniemi, YA | 1 |
Grundy, SM | 1 |
Hutt, V | 3 |
Wechsler, JG | 2 |
Klör, HU | 3 |
Ditschuneit, H | 3 |
Soler, J | 1 |
Vinzia, C | 1 |
Gómez, JM | 1 |
Morató, J | 1 |
Jäger, E | 1 |
Kefalides, A | 1 |
Clopath, P | 1 |
Sinzinger, H | 1 |
Miettinen, TA | 1 |
Huttunen, JK | 1 |
Ehnholm, C | 1 |
Kumlin, T | 1 |
Mattila, S | 1 |
Naukkarinen, V | 1 |
Vogelberg, KH | 1 |
Dannehl, K | 1 |
Gries, FA | 1 |
Reuter, W | 2 |
Neuman, MP | 1 |
Kurlat, MI | 1 |
Neuman, J | 1 |
Nash, DT | 1 |
Carvalho, AC | 1 |
Lees, RS | 1 |
Olsson, AG | 1 |
Orö, L | 1 |
Altomonte, L | 2 |
Mingrone, G | 2 |
Negrini, A | 1 |
De Cunto, F | 1 |
Greco, AV | 2 |
Ferreira, IJ | 1 |
del Rio, A | 1 |
González-Viejo, N | 1 |
Vicens, B | 1 |
Havel, RJ | 1 |
Kane, JP | 1 |
Ferreira Montero, IJ | 1 |
Gutiérrez Martín, M | 1 |
del Río Ligorit, A | 1 |
Casasnovas Lenguas, JA | 1 |
Cornudella Lacasa, R | 1 |
Schwandt, P | 2 |
Weisweiler, P | 2 |
Drosner, M | 1 |
Janetschek, P | 1 |
Schwartzkopff, W | 3 |
Luley, C | 2 |
Scheffler, W | 2 |
Lehmann-Leo, W | 1 |
Schilling, A | 3 |
Wegscheider, K | 1 |
Vessby, B | 2 |
Lithell, H | 2 |
Ledermann, H | 1 |
Naruszewicz, M | 2 |
Nowicka, G | 1 |
Szostak, WB | 2 |
Kłosiewicz-Latoszek, L | 1 |
Ziegler, WJ | 2 |
Metz, G | 1 |
Specker, M | 1 |
Vorberg, G | 1 |
Ditschuneit, HH | 1 |
Kritchevsky, D | 1 |
Sale, JK | 1 |
Johnstone, JH | 1 |
Mühlfellner, G | 1 |
Mühlfellner, O | 1 |
Ghirlanda, G | 1 |
Manna, R | 1 |
Rebuzzi, A | 1 |
Pala, MA | 1 |
Calder, D | 2 |
Wolfe, BM | 1 |
Ahuja, SP | 1 |
Marliss, EB | 1 |
Cybulska, C | 1 |
Kozłowska, M | 1 |
Chotkowska, E | 1 |
Sznajderman, M | 1 |
Brook, JG | 1 |
Lavy, A | 1 |
Aviram, M | 1 |
Zinder, O | 1 |
Noseda, G | 1 |
Fragiacomo, C | 1 |
Weidmann, P | 1 |
Bachmann, C | 1 |
Rajecová, E | 1 |
Klimes, I | 1 |
Seböková, E | 1 |
Rychnavská, E | 1 |
Pleváková, L | 1 |
Linke-Cvrkalová, A | 1 |
Langrová, H | 1 |
Gustafsson, IB | 1 |
Borberg, J | 1 |
Colombo, L | 1 |
Monarca, A | 1 |
Goldberg, D | 1 |
Zanetta, R | 1 |
Bolzano, K | 1 |
Krempler, F | 1 |
Schellenberg, B | 1 |
Schlierf, G | 1 |
Oikawa, S | 1 |
Rodriguez, F | 1 |
López, IM | 1 |
Jover, E | 1 |
Gotto, AM | 1 |
Jones, PH | 1 |
Scott, LW | 1 |
Brown, WV | 1 |
Stuyt, PM | 1 |
Stalenhoef, AF | 1 |
Demacker, PN | 1 |
Van 't Laar, A | 1 |
Lipovetskiĭ, BM | 1 |
Triufanov, VF | 1 |
Teriukova, NP | 1 |
Nestruck, AC | 1 |
Pande, SV | 1 |
Davignon, J | 1 |
Parker, F | 1 |
3 reviews available for clofibrate and Carbohydrate Inducible Hyperlipemia
Article | Year |
---|---|
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Comb | 1982 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
9 trials available for clofibrate and Carbohydrate Inducible Hyperlipemia
Article | Year |
---|---|
Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Clofibrate; Fatty Alcohols; Female; Humans; Hy | 1983 |
Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
Topics: Antihypertensive Agents; Apolipoproteins; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipopro | 1980 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1981 |
Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
Topics: Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipo | 1981 |
[Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1982 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; | 1982 |
[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia | 1980 |
[Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; | 1980 |
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Choleste | 1985 |
40 other studies available for clofibrate and Carbohydrate Inducible Hyperlipemia
Article | Year |
---|---|
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Effect of hypertriglyceridemia and its treatment on tetracycline pharmacokinetics].
Topics: Adult; Clofibrate; Doxycycline; Drug Interactions; Humans; Hyperlipoproteinemia Type IV; Kinetics; M | 1984 |
Clofibrate, caloric restriction, supersaturation of bile, and cholesterol crystals.
Topics: Aged; Bile Acids and Salts; Cholesterol; Clofibrate; Crystallization; Energy Intake; Female; Humans; | 1983 |
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
[Plafibride treatment of hyperlipidemias type II and IV].
Topics: Adult; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperl | 1984 |
The effect of clofibrate on plasma factor and vascular prostacyclin-synthesis.
Topics: Adult; Animals; Aorta; Blood Vessels; Clofibrate; Diet, Atherogenic; Epoprostenol; Humans; Hyperlipo | 1982 |
[Disorders of glucose metabolism and manifestation of diabetes during treatment of endogenous hypertriglyceridemias (author's transl)].
Topics: Adult; Aged; Blood Glucose; Cholesterol; Clofibrate; Diabetes Mellitus; Diet, Reducing; Female; Gluc | 1981 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; | 1983 |
Gemfibrozil--a new lipid lowering agent.
Topics: Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; | 1980 |
Platelets intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thrombo-embolic complications.
Topics: Adenine Nucleotides; Adult; Blood Coagulation Disorders; Blood Platelets; Clofibrate; Factor XII; Fi | 1980 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
Topics: Apolipoprotein C-I; Apolipoprotein C-II; Apolipoproteins; Apolipoproteins C; Apolipoproteins E; Beza | 1982 |
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia | 1982 |
[Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
Topics: Adult; Aged; Cholesterol Esters; Clofibrate; Clofibric Acid; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; | 1982 |
[Clinical effects and tolerance of etofylline clofibrate].
Topics: Clofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hy | 1980 |
[Pharmacology of fenofibrate (author's transl)].
Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyper | 1980 |
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoprote | 1980 |
Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
Topics: Cholesterol; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1981 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperli | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
Mechanism of the hypolipemic effect of clofibrate in glucose-fed men.
Topics: Adult; Amino Acids; Clofibrate; Fasting; Fatty Acids, Nonesterified; Glucose; Glycerol; Humans; Hype | 1980 |
The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
Topics: Adult; Aged; Blood Proteins; Cholesterol; Clofibrate; Female; Humans; Hyperlipoproteinemia Type IV; | 1980 |
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyp | 1980 |
The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemia Type IV; Lipoproteins, HDL | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipopro | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipopr | 1980 |
[Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Topics: Clofibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoprotei | 1995 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1979 |
[Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
Topics: Clofibrate; Fatty Alcohols; Gastrointestinal Diseases; Headache; Humans; Hyperlipidemias; Hyperlipop | 1979 |
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Huma | 1979 |
[Endogenous hypertriglyceridemia].
Topics: Clofibrate; Coronary Artery Disease; Diet; Exercise Therapy; Female; Humans; Hyperlipoproteinemia Ty | 1992 |
Plafibride treatment and serum lipids in hyperlipoproteinemias.
Topics: Adolescent; Adult; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diet; Female; Humans; Hyp | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
[Differential use of diet and drugs in dyslipoproteinemias].
Topics: Adult; Clofibrate; Dietary Carbohydrates; Dietary Fats; Female; Humans; Hyperlipoproteinemia Type II | 1985 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |